Literature DB >> 11004343

Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer?

A Imdahl1, J Jenkner, C Ihling, K Rückauer, E H Farthmann.   

Abstract

BACKGROUND: The overall survival rate for patients with an esophageal cancer remains poor. As a consequence, preoperative chemoradiation was introduced for patients with tumor stage T >1 M0 regardless of tumor histology or localization. However, factors predicting response to this therapy pretherapeutically are largely unknown.
METHODS: Clinical results of preoperative chemoradiation were investigated. The rates of proliferation and apoptosis were determined in pretherapeutic tumor samples and correlated with tumor response and long-term survival after surgery.
RESULTS: A complete tumor response due to chemoradiation (n = 42; cervically localized tumors excluded) was achieved in 11 patients (26%) after resection. Five-year survival rate was significantly improved in these patients compared with those who did not respond to chemoradiation (48% versus 5.5%; P = 0.003). Chemoradiation was performed without benefit in 43%. Perioperative hospital mortality rate was 14.3% in all patients. No correlation of apoptosis with response to chemoradiation or postoperative long-term survival was observed. However, there was a clear correlation between the proliferation rate as determined by MIB-1 immunohistology. Five-year survival rate of patients with a proliferation index (PI) >/=39% was 38% compared with 0% in tumors with a PI <39%. Tumors with a PI >/=39% responded to chemoradiation in 71.4%, but 100% of tumors with a PI <39% did not. Mean survival time of these patients was 33 months and 11 months, respectively (P = 0.015).
CONCLUSIONS: The results indicate that the PI may be used for stratification of patients treatment prior surgery. However, these results need further validation in larger patient numbers in the search for factors indicating response pretherapeutically to preoperative chemoradiation in esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11004343     DOI: 10.1016/s0002-9610(00)00386-x

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  5 in total

1.  Methyl-methanesulfonate sensitivity 19 expression is associated with metastasis and chemoradiotherapy response in esophageal cancer.

Authors:  Jin-Liang Zhang; Hui-Yun Wang; Qing Yang; Shi-Yong Lin; Guang-Yu Luo; Rong Zhang; Guo-Liang Xu
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

2.  Individual cell-based models of tumor-environment interactions: Multiple effects of CD97 on tumor invasion.

Authors:  Joerg Galle; Doreen Sittig; Isabelle Hanisch; Manja Wobus; Elke Wandel; Markus Loeffler; Gabriela Aust
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

3.  Response to chemoradiatiotherapy in squamous cell carcinoma of the esophagus: evaluation of some prognostic factors.

Authors:  Dag Stockeld; Ursula Falkmer; Sture Falkmer; Lars Backman; Lars Granström; Jan Fagerberg
Journal:  Clin Exp Gastroenterol       Date:  2009-04-24

4.  The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma.

Authors:  S Dutta; J J Going; A B C Crumley; Z Mohammed; C Orange; J Edwards; G M Fullarton; P G Horgan; D C McMillan
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

5.  Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy.

Authors:  Hiroshi Okamoto; Fumiyoshi Fujishima; Takashi Kamei; Yasuhiro Nakamura; Yohei Ozawa; Go Miyata; Toru Nakano; Kazunori Katsura; Shigeo Abe; Yusuke Taniyama; Tadashi Sakurai; Jin Teshima; Makoto Hikage; Hironobu Sasano; Noriaki Ohuchi
Journal:  BMC Cancer       Date:  2015-03-31       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.